PART 3
Metastatic Breast Cancer Management
CDK 4/6 ,
mTOR
Bone and soft tissue metastases tend to have a better prognosis and are more likely to respond to
endocrine therapy.
Symptomatic visceral metastases generally require chemotherapy due to need for rapid response.
CASE 5:
GS is a 62-year-old female who presents with MBC to the bone. She
was originally diagnosed with stage IIB ER-negative, PR-negative,
HER2 positive (IHC 3+) breast cancer 10 years ago and received
treatment with lumpectomy, adjuvant chemotherapy with TAC x 6
cycles, followed by radiation and 1 year of trastuzumab. She has
mild bone pain that is controlled with an NSAID. Biopsy of her
recurrent disease is consistent with the original tumor pathology.
Which of the following regimens is the most appropriate
option for GS at this time?
A. Trastuzumab alone
B. Pertuzumab + docetaxel
C. Trastuzumab + lapatinib
D. Trastuzumab + pertuzumab + docetaxel
CASE 5:
GS is a 62-year-old female who presents with MBC to the bone. She
was originally diagnosed with stage IIB ER-negative, PR-negative,
HER2 positive (IHC 3+) breast cancer 10 years ago and received
treatment with lumpectomy, adjuvant chemotherapy with TAC x 6
cycles, followed by radiation and 1 year of trastuzumab. She has
mild bone pain that is controlled with an NSAID. Biopsy of her
recurrent disease is consistent with the original tumor pathology.
Which of the following regimens is the most appropriate
option for GS at this time?
A. Trastuzumab alone
B. Pertuzumab + docetaxel
C. Trastuzumab + lapatinib
D. Trastuzumab + pertuzumab + docetaxel
